Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Bone Marrow Stromal Cells Generate Muscle Cells and Repair Muscle Degeneration
Mari Dezawa,1*Hiroto Ishikawa,1Yutaka Itokazu,1Tomoyuki Yoshihara,1Mikio Hoshino,2Shin-ichi Takeda,3Chizuka Ide,1Yo-ichi Nabeshima2
Bone marrow stromal cells (MSCs) have great potential as therapeuticagents. We report a method for inducing skeletal muscle lineagecells from human and rat general adherent MSCs with an efficiencyof 89%. Induced cells differentiated into muscle fibers upontransplantation into degenerated muscles of rats and mdx-nudemice. The induced population contained Pax7-positive cells thatcontributed to subsequent regeneration of muscle upon repetitivedamage without additional transplantation of cells. These MSCsrepresent a more ready supply of myogenic cells than do therare myogenic stem cells normally found in muscle and bone marrow.
1 Department of Anatomy and Neurobiology, Kyoto University Graduate School of Medicine, Yoshidakonoecho, Sakyo-ku, Kyoto, 606-8501 Japan. 2 Department of Pathology and Tumor Biology, Kyoto University Graduate School of Medicine, Yoshidakonoecho, Sakyo-ku, Kyoto, 606-8501 Japan. 3 Department of Molecular Therapy, National Center of Neurology and Psychiatry, Kodaira, 187-8502 Tokyo, Japan.
* To whom correspondence should be addressed. E-mail: dezawa{at}anat2.med.kyoto-u.ac.jp
The Small Molecule Phenamil Induces Osteoblast Differentiation and Mineralization.
K. W. Park, H. Waki, W.-K. Kim, B. S. J. Davies, S. G. Young, F. Parhami, and P. Tontonoz (2009)
Mol. Cell. Biol.
29, 3905-3914
|Abstract »|Full Text »|PDF »
Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts.
A. Zibat, A. Uhmann, F. Nitzki, M. Wijgerde, A. Frommhold, T. Heller, V. Armstrong, L. Wojnowski, L. Quintanilla-Martinez, J. Reifenberger, et al. (2009)
Carcinogenesis
30, 918-926
|Abstract »|Full Text »|PDF »
Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen.
A. Shabbir, D. Zisa, G. Suzuki, and T. Lee (2009)
Am J Physiol Heart Circ Physiol
296, H1888-H1897
|Abstract »|Full Text »|PDF »
Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells.
K. Otsu, S. Das, S. D. Houser, S. K. Quadri, S. Bhattacharya, and J. Bhattacharya (2009)
Blood
113, 4197-4205
|Abstract »|Full Text »|PDF »
Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model.
C. Kyriakou, N. Rabin, A. Pizzey, A. Nathwani, and K. Yong (2008)
Haematologica
93, 1457-1465
|Abstract »|Full Text »|PDF »
Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.
E. Kimura, J. J. Han, S. Li, B. Fall, J. Ra, M. Haraguchi, S. J. Tapscott, and J. S. Chamberlain (2008)
Hum. Mol. Genet.
17, 2507-2517
|Abstract »|Full Text »|PDF »
Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells".
R. Atoui, D. Shum-Tim, and R. C.J. Chiu (2008)
Ann. Thorac. Surg.
86, 327-334
|Abstract »|Full Text »|PDF »
cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo.
R. Siddappa, A. Martens, J. Doorn, A. Leusink, C. Olivo, R. Licht, L. van Rijn, C. Gaspar, R. Fodde, F. Janssen, et al. (2008)
PNAS
105, 7281-7286
|Abstract »|Full Text »|PDF »
Bisperoxovanadium, a phospho-tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype.
L. Castaldi, C. Serra, F. Moretti, G. Messina, R. Paoletti, M. Sampaolesi, A. Torgovnick, M. Baiocchi, F. Padula, A. Pisaniello, et al. (2007)
FASEB J
21, 3573-3583
|Abstract »|Full Text »|PDF »
Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells.
T. Rubinek, V. Chesnokova, I. Wolf, K. Wawrowsky, G. Vlotides, and S. Melmed (2007)
Am J Physiol Cell Physiol
293, C1082-C1092
|Abstract »|Full Text »|PDF »
A high-throughput siRNA library screen identifies osteogenic suppressors in human mesenchymal stem cells.
Menstrual Blood-derived Cells Confer Human Dystrophin Expression in the Murine Model of Duchenne Muscular Dystrophy via Cell Fusion and Myogenic Transdifferentiation.
C.-H. Cui, T. Uyama, K. Miyado, M. Terai, S. Kyo, T. Kiyono, and A. Umezawa (2007)
Mol. Biol. Cell
18, 1586-1594
|Abstract »|Full Text »|PDF »
Myogenic potential of adipose-tissue-derived cells.
G. Di Rocco, M. G. Iachininoto, A. Tritarelli, S. Straino, A. Zacheo, A. Germani, F. Crea, and M. C. Capogrossi (2006)
J. Cell Sci.
119, 2945-2952
|Abstract »|Full Text »|PDF »
The satellite cell as a companion in skeletal muscle plasticity: currency, conveyance, clue, connector and colander.
T. Partridge (2006)
N. Engl. J. Med.
354, 1844-1845
|Full Text »|PDF »
Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion.
M. A.F.V. Goncalves, A. A.F. de Vries, M. Holkers, M. J.M. van de Watering, I. van der Velde, G. P. van Nierop, D. Valerio, and S. Knaan-Shanzer (2006)
Hum. Mol. Genet.
15, 213-221
|Abstract »|Full Text »|PDF »
Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb.
C. Napoli, S. Williams-Ignarro, F. de Nigris, G. de Rosa, L. O. Lerman, B. Farzati, A. Matarazzo, G. Sica, C. Botti, A. Fiore, et al. (2005)
PNAS
102, 17202-17206
|Abstract »|Full Text »|PDF »
